Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.

Hutchison China Meditech (HCM)     

dreamcatcher - 07 Aug 2012 21:04




Hutchison China MediTech Limited ("Chi-Med") is a China-based globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.

Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is listed on the London Stock Exchange’s AIM market (AIM: HCM). It is majority owned by CK Hutchison Holdings Limited (SEHK: 0001), a leading international conglomerate committed to innovation and technology with over a quarter of a million employees in more than 50 countries and annual sales of over US$50 billion.

http://www.chi-med.com/eng/global/home.php


free counters
Chart.aspx?Provider=EODIntra&Code=HCM&SiChart.aspx?Provider=EODIntra&Code=HCM&Si

dreamcatcher - 22 Nov 2013 16:51 - 49 of 190

IC this week continue to rate the shares a buy. Game changer, aim company with 10 bagger innovations.

dreamcatcher - 29 Nov 2013 20:51 - 50 of 190

In IGI this week - Mark Slater Boasting a 'huge pipeline of products' 'I think the shares could double from here quite easily'.

dreamcatcher - 18 Dec 2013 15:41 - 51 of 190


Sinopharm distribution joint venture in China

RNS


RNS Number : 8467V

Hutchison China Meditech Limited

18 December 2013












Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Chi-Med and Sinopharm form China drug distribution and marketing joint venture





London: Wednesday, 18 December 2013: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces the establishment of a new joint venture with Sinopharm Group Co. Ltd. ("Sinopharm"). Sinopharm is the largest distributor of pharmaceutical and healthcare products and a leading value added supply chain service provider in China. The joint venture will provide distribution and marketing services to both related and third party pharmaceutical companies in China.



Chi-Med will, through a wholly-owned subsidiary, invest approximately US$9.8 million in cash into Sinopharm Holding HuYong Pharmaceutical (Shanghai) Co., Ltd. ("Huyong") for the subscription of 51% of the equity in the enlarged share capital of Huyong, which will mean that Huyong will be consolidated as a Chi-Med subsidiary. The Chi-Med investment will be largely deployed for expanding future commercial activities, particularly in the area of third party drug sales and marketing. Sinopharm will hold the balance of 49% of the equity in Huyong.



Huyong is a Good Supply Practice ("GSP") certified pharmaceutical and healthcare distribution and marketing company that was originally established in 1993 and subsequently acquired by Sinopharm in 2010. Huyong will be renamed as Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"). Huyong's profit before tax for the year ended 31 December 2012 was US$1.0 million, and had gross assets at 31 December 2012 of US$29.9 million.



Hutchison Sinopharm will be reported under the China Healthcare Division of Chi-Med which currently comprises three companies: Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS"); Shanghai Hutchison Pharmaceuticals Limited ("SHPL"); and Hutchison Healthcare Limited ("HHL"). The 2012 sales of the China Healthcare Division subsidiaries and jointly controlled entities of Chi-Med were US$350.5 million and net profit attributable to Chi-Med equity holders was US$15.5 million.



Hutchison Sinopharm will provide a platform for synergy across the China Healthcare Division of Chi-Med by utilising the services of the approximately 2,800-person prescription drug and over-the-counter drug sales teams of SHPL and HBYS. A major aspect of the Hutchison Sinopharm business strategy will be to provide sales, distribution, and marketing services to major domestic and multi-national third party pharmaceutical manufacturers. It will also provide a broadened sales and marketing platform for HHL's products and potentially the future novel drugs registered by Hutchison MediPharma Limited, Chi-Med's Drug R&D Division.



This transaction is subject to regulatory approval in China.



Christian Hogg, Chi-Med CEO said: "This strategic investment widens the scope of our China Healthcare Division dramatically by allowing Chi-Med's commercial organisation to market third party pharmaceutical products. We are honoured to partner with Sinopharm in the area of drug distribution and marketing and expect to build a material business based on the complementary strengths of our two groups over the coming years."

dreamcatcher - 15 Jan 2014 16:40 - 52 of 190

Chart.aspx?Provider=EODIntra&Code=HCM&Si

dreamcatcher - 16 Jan 2014 15:44 - 53 of 190


Notice of Results

RNS


RNS Number : 6998X

Hutchison China Meditech Limited

16 January 2014














Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Notice of Announcement of 2013 Final Results





London: Thursday, 16 January 2014: Chi-Med will be announcing its final results for the year ended 31 December 2013 on Tuesday, 18 February 2014. An analyst presentation will be held at 9:00am on the same day at Panmure Gordon, 3rd Floor, One New Change, London, EC4M 9AF.





Ends

dreamcatcher - 18 Feb 2014 07:11 - 54 of 190


Final Results

RNS


RNS Number : 2681A

Hutchison China Meditech Limited

18 February 2014














Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Final Results for the year ended 31 December 2013

Continued momentum. Continued very considerable growth potential.



London: Tuesday, 18 February 2014: Chi-Med today announces its final results for the year ended 31 December 2013.



Consolidated Group Results (IFRS11)

· Revenue from continuing operations up 106% to $46.0 million (2012: $22.4m), not including sales at the JV level which totalled $390.6 million (2012: $345.3m).

· Operating profit up 65% to $9.6 million (2012: $5.8m) including non-recurring charge of $2.0 million.

· Net profit attributable to Chi-Med equity holders up 63% to $5.9million (2012: $3.6m).

· Cash and cash equivalents at the Chi-Med Group level of $46.9 million (31 December 2012: $30.8m) in addition, and not included at the Group level, cash and cash equivalents held at the JV level totalled $99.0 million (31 December 2012: $62.4m).



Results are reported in US dollar currency unless otherwise stated.



Christian Hogg, Chi-Med CEO, said: "Chi-Med has had a highly successful 2013. We have propelled our revenues and profit, and the drivers of this success are set to continue.



Our Drug R&D Division has taken a major step forward by signing a new licensing deal with Eli Lilly and cementing its collaboration with Janssen to add to those it already has with AstraZeneca and Nestlé Health Science. Its revenues have increased sharply due to payments from these partners. It has significantly progressed its six clinical stage drug candidates either reaching, or closing in on, proof-of-concept. We have spent over $30 million on clinical trials in 2013, with our partners funding the great majority of these clinical costs. Several of our compounds in clinical development showed impressive results in 2013 - in two cases for treatment of certain tumour types, for which there are few, if any, treatment options approved on the global market.



By the end of 2013, Chi-Med had received $72 million of upfront and milestone payments and equity injections from our four partners. Looking ahead, this cash flow should escalate. In addition to funding the vast majority of clinical costs on our partnered drug candidates, our partners will contribute, subject to clinical success, up to approximately $1.2 billion in development, approval, and commercial milestones and option payments, as well as customary royalties on net sales.



Our China Healthcare Division continues to grow rapidly with net profit attributable to Chi-Med equity holders up 20% in 2013, again demonstrating the major potential in the China pharmaceutical market. Its sales and profitability are now benefitting from the normalisation of raw material prices and, this year, we hope to start crystallising the value in our manufacturing property portfolio. To take advantage of the opportunity for Chi-Med to provide sales, distribution and marketing services to major Chinese and multi-national third party pharmaceutical manufacturers as well as our own Drug R&D Division, we have formed a joint venture with Sinopharm.



Our Consumer Products Division grew sales 23%, driven by the progress of Hutchison Hain Organic, while Sen France and aspects of our China infant formula businesses have been discontinued.



Trading has started well this year. Sales and profit in our China Healthcare Division are well ahead of 2013 levels, as a result of effective execution and continued normalisation of raw material costs. We expect 2014 to be a breakout year for our Drug R&D Division as we publish clinical data on Volitinib, Fruquintinib and Sulfatinib, in each case outlining next stage clinical plans. On HMPL-004 we will reach our Interim Analysis on NATRUL-3, our Phase III induction study, and publish status in mid-2014. We expect also to start Phase I trials on our spleen tyrosine kinase ("Syk") inhibitor for inflammation in Australia, which would elevate the profile of this very high potential programme. Our Consumer Products Division's continuing operations have started well and we expect the refocused operations to be profitable this year.



The opportunities facing us are very considerable and we believe we will deliver further substantial shareholder value this year and beyond."



Highlights

China Healthcare Division - Continuing strong growth

· Sales of subsidiaries and joint ventures ("JVs") up 13% to $394.6 million (2012: $350.5m). Organic expansion of own brands (up 14% to $343.0m) with both prescription and over-the-counter ("OTC") cardiovascular drug sales being the strongest. Third party OTC drug distribution business up only 2% to $51.6 million due to shedding of lower margin activity.

· Net profit attributable to Chi-Med equity holders up 20% to $18.6 million (2012: $15.5m).

· Entered into an agreement to establish a new 51% Chi-Med owned JV, subject to regulatory approval, with Sinopharm Group Co. Ltd. (HKSE:1099) ("Sinopharm") to provide sales, distribution, and marketing services to major Chinese and multi-national third party pharmaceutical manufacturers.



Drug R&D Division - Step-change developments approaching

· Revenue up 327% to $29.5 million (2012: $6.9m) as a result of $22.2 million in upfront and milestone income and $7.3 million in service income from our partners.

· Secured $54.8 million in third party cash injections for Hutchison MediPharma Limited's ("HMP") activities during 2013, bringing the total to $103.6 million since 2010.

· Net lossattributable to Chi-Med equity holders of $2.4 million (2012: net profit $2.8m) due primarily to the consolidation of $8.8 million (2012: nil) non-cash share of the loss of Nutrition Science Partners Limited ("NSP"), the JV with Nestlé Health Science SA ("Nestlé Health Science"). NSP, which is enrolling patients in the HMPL-004 global Phase III registration trial, was entirely self-funded in 2013, and will be until the Interim Analysis in mid-2014, by the initial cash equity investment in NSP by Nestlé Health Science.

· Progressed global development of Volitinib (HMPL-504), a c-Met inhibitor in oncology, in partnership with AstraZeneca AB (publ) ("AstraZeneca") in Phase I in Australia and China. Phase I dose escalation, initiation of which triggered a $5 million milestone in mid-2013, will be completed by early 2014 and results will be published at the American Society of Clinical Oncology ("ASCO") meetings in June 2014. Volitinib has demonstrated very encouraging anti-tumour activity in Phase I in certain tumour-types, some of which have no approved therapies on the global market. Phase II studies in papillary renal cell carcinoma ("PRCC") will start in early 2014 in the United States and global Phase III initiation is scheduled for 2015.

· Completed exclusive license and collaboration agreement for China with Eli Lilly and Company ("Lilly") on Fruquintinib (HMPL-013), our highly selective vascular endothelial growth factor receptor ("VEGFR") inhibitor. Lilly will share development costs and pay HMP up to $86.5 million in upfront payments and development and regulatory milestones and upon commercialisation in China tiered royalties starting in the mid-teens percentage of net sales. Fruquintinib, which received Phase II/III clearance from the China Food & Drug Administration ("CFDA") in mid-2013, will start Phase II studies in several tumour types, and a Phase III registration study on one tumour type, in China in 2014.

· Immunology collaboration with Janssen Pharmaceuticals, Inc. ("Janssen"), the pharmaceutical division of Johnson & Johnson, progressed well in 2013. Janssen nominated a compound, HMPL-507, discovered by HMP, for further development thereby triggering a $6 million milestone payment. Janssen will be responsible for all development costs and will potentially pay HMP up to an additional $90.5 million in development and regulatory approval milestones, and royalties on worldwide sales upon commercialisation.

· Beyond the four partnered drug candidates, HMP has effectively progressed three further high potential small molecule oncology drug candidates with stand-out results on Sulfatinib which in 2013 demonstrated very encouraging anti-tumour activity in certain tumour types, some of which have very limited treatment options approved on the global market.

· In discovery, HMP nominated HMPL-523 in early 2013, a novel Syk inhibitor, for rheumatoid arthritis and intends to start Phase I trials in Australia in early 2014.



Consumer Products Division - Refocused

· Sales on continuing operations up 23% to $12.5 million (2012: $10.2m) driven by progress on the expansion of the range of Hutchison Hain Organic Holdings Limited ("HHO") products in Asia.

· Non-recurring $2.0 million in costs associated with the discontinuation of the Sen France and aspects of the China infant formula businesses.

· Net loss attributable to Chi-Med equity holders on continuing operations of $0.5 million (2012: -$0.9m).



Group results are reported for the full year for the first time under IFRS11 "Joint Arrangements" ("IFRS11"), which establishes the equity accounting principle for the reporting of JVs and means that the income statements and statements of financial position of JVs will no longer be proportionately consolidated. However, total revenues of the JVs will continue to be disclosed throughout the announcement.



A presentation for analysts will be held at 9:00 a.m. today at the offices of Panmure Gordon at 3rd Floor, One New Change, London EC4M 9AF.

The Annual General Meeting of Chi-Med will be held at 4th Floor, Hutchison House, 5 Hester Road, Battersea, London SW11 4AN on Thursday, 8 May 2014 at 10:00 a.m.



Ends

dreamcatcher - 21 Feb 2014 15:57 - 55 of 190

Hutchison China MediTech Ltd (HCM:LSE) set a new 52-week high during today's trading session when it reached 735.00. Over this period, the share price is up 67.05%.

dreamcatcher - 24 Feb 2014 17:23 - 56 of 190

A buy in last weeks IC

dreamcatcher - 25 Feb 2014 17:40 - 57 of 190

Doing very well since the new year.

dreamcatcher - 04 Mar 2014 18:24 - 58 of 190

Edison - Valuation: Increased to $791m (932p a share)
Updating our sum-of-the-parts model for the FY13 results and the progress in the R&D pipeline sees our valuation rising from $577m (705p a share) to $791m (932p a share) – ex property windfalls. MediPharma is valued, using an rNPV, at $257m (303p a share); placing China Healthcare on a peer group rating gives $505m (595p per share); with Consumer Products adding $36m (42p a share). Netting out group net cash/debt results in our $791m (932p a share) value.

dreamcatcher - 11 Mar 2014 17:19 - 59 of 190

Hutchison China MediTech Ltd (HCM:LSE) set a new 52-week high during today's trading session when it reached 900.00. Over this period, the share price is up 104.55%.

Chart.aspx?Provider=EODIntra&Code=HCM&Si

dreamcatcher - 12 Mar 2014 14:23 - 60 of 190

Really Taken off in March, a new high.

Hutchison China MediTech Ltd (HCM:LSE) set a new 52-week high during today's trading session when it reached 973.00. Over this period, the share price is up 121.14%.

dreamcatcher - 13 Mar 2014 21:24 - 61 of 190

Shares - has stated that Huchison MediTech Ltd in the coming months is poised to close a number of deals. In the light of the Chinese newsflow it demands caution.

dreamcatcher - 14 Mar 2014 18:36 - 62 of 190

Hutchison China MediTech: UBS raises target price from 820p to 1000p, but downgrades from buy to neutral.

dreamcatcher - 02 Apr 2014 16:06 - 63 of 190

Hutchison China Meditech: Panmure Gordon increases target price from 750p to 950p and stays with its buy recommendation.

dreamcatcher - 04 Apr 2014 15:44 - 64 of 190


Presentations at the 2014 AACR Annual Meeting

RNS


RNS Number : 0130E

Hutchison China Meditech Limited

04 April 2014






Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Presentations of volitinib and epitinib data at the 2014 AACR Annual Meeting



London: Friday, 4 April 2014: Chi-Med today announces that data from certain preclinical and clinical studies by Hutchison MediPharma Limited ("HMP"), its majority owned R&D company, will be presented at the 105th Annual Meeting of the American Association for Cancer Research ("AACR") to be held in San Diego, California, USA from 5 to 9 April 2014. These presentations will include additional data on volitinib (HMPL-504/AZD6094) and epitinib (HMPL-813), two novel and highly selective small molecule drugs discovered by HMP. Presentations on volitinib were prepared jointly with HMP's collaboration partner AstraZeneca AB (publ) ("AstraZeneca").



AACR is the world's first and largest professional organisation dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees.



HMP will have one oral presentation encompassing the substantial research and early clinical evaluation of volitinib, as well as two poster presentations focused specifically on c-Met models in preclinical studies of volitinib, and on epidermal growth factor receptor ("EGFR") inhibition in oesophagus cancer.

dreamcatcher - 17 Apr 2014 07:09 - 65 of 190


Chi-Med and Sinopharm Deal Approved

RNS


RNS Number : 0531F

Hutchison China Meditech Limited

17 April 2014














Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Chi-Med and Sinopharm complete regulatory approval for the establishment of new China drug distribution and marketing Joint Venture





London: Thursday, 17 April 2014: Following the announcement on Wednesday, 18 December 2013, Chi-Med today announces that Chi-Med and Sinopharm Group Co. Ltd. ("Sinopharm") (SEHK:1099) have received regulatory approval for the establishment of their new joint venture, Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm") (formerly known as Sinopharm Holding HuYong Pharmaceutical (Shanghai) Co., Ltd.). Hutchison Sinopharm, which formally commences operations on 25 April 2014, is 51% held by Chi-Med and will be consolidated as a Chi-Med subsidiary and reported under its China Healthcare Division.



Sinopharm is the largest distributor of pharmaceutical and healthcare products and a leading value added supply chain service provider in China. The purpose of Hutchison Sinopharm is to provide sales, distribution, and marketing services to major domestic and multi-national third party pharmaceutical manufacturers. It will also provide a broadened sales and marketing platform for synergy across Chi-Med group.





Ends

dreamcatcher - 09 May 2014 20:50 - 66 of 190


Mark Slater's winning shares

The Zulu Principle also places heavy emphasis on a catalyst being in place to help drive shares higher, an aspect highlighted by some of the winners that Slater’s fund has thrown up in recent years.


Parents will need no introduction to the catalyst that lies behind the success of the fund’s most famous winner, Entertainment One, which has posted huge gains off the back of its all-conquering cartoon show Peppa Pig.


It is a member of the illustrious ten-bagger club of shares that have risen at least tenfold, with its price soaring from below 20p during the 2009 market lows to just a few pence shy of 300p now. It has been a star performer since Slater bought in 2010 – he tipped This is Money readers as to why he was a buyer back in 2011.


Entertainment One remains in the fund’s top ten shares but is now the seventh biggest holding, after Slater took some profits from a stock that was his second biggest asset at the start of the year and had posted a 54 per cent gain in 2013.


Slater’s biggest holding is one of his stalwarts, Hutchison China Meditech. This is the UK-listed holding company of a healthcare group based in China, which has a strong growth record and net cash and surplus property on its books.


He describes the firm’s main business as having a wonderful tailwind from government health spending, demographics and rising living standards, adding that while ‘China would normally fill us with fear’ this is a subsidiary of Hutchison Whampoa, which is largely owned by Li Ka-shing – a man dubbed Asia’s Warren Buffett.


The fund’s holding in Hutchison China Meditech has risen from about 180p to around 800p. Slater likes it because he believes it also contains some unrecognised value. It includes a research and development business which is a Chinese biotech leader, has invested heavily in oncology and immunology therapies and is partnering with major Western pharmaceutical companies on potential blockbuster drugs. He says: ‘This is a very nice kicker to have.’


The manager cites consulting and software firm First Derivatives as another share with great potential thanks to its opportunity to expand through big data, and describes data storage firm Restore as a very steady, very fast growing company with a reliable customer base.


Among the other shares he highlights now are engineer Pressure Technologies and energy cost specialist UtilityWise.

Slater likes to hold between 25 and 50 shares in the fund and a glance at the fund’s top holdings right now could lead investors to believe he was a smaller companies specialist, but Slater says he is not concerned about size


'There is a bigger upside in smaller and medium sized companies but we do screen across the board. On occasion we have owned a lot of large companies,’ he says.


http://www.dailymail.co.uk/money/investing/article-2624331/Invest-growth-dont-overpay-Star-fund-manager-Mark-Slaters-tips.html

dreamcatcher - 19 May 2014 19:01 - 67 of 190

Hutchison China MediTech: UBS upgrades from neutral to buy with a target price of 1000p.

dreamcatcher - 22 May 2014 07:08 - 68 of 190


Phase I data to be presented at ASCO

RNS


RNS Number : 6785H

Hutchison China Meditech Limited

22 May 2014






Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Phase I clinical data for selective VEGFR, c-Met and VEGFR/FGFR inhibitors to be presented at the 2014 ASCO Annual Meeting



London: Thursday, 22 May 2014: Chi-Med today announces that data from recent Phase I and Phase Ib clinical studies by Hutchison MediPharma Limited ("HMP"), its majority owned R&D company, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology ("ASCO") to be held in Chicago, Illinois, USA from 30 May to 3 June 2014. These presentations will include additional data on fruquintinib (HMPL-013), AZD6094 (HMPL-504/volitinib) and sulfatinib (HMPL-012), three novel and highly selective small molecule drugs discovered by HMP. Presentations on AZD6094 were prepared jointly with HMP's collaboration partner AstraZeneca AB (publ) ("AstraZeneca").



ASCO is a non-profit organisation founded in 1964 with the goals of improving cancer care and prevention. Nearly 30,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. The ASCO Annual Meeting brings these people together to find cutting-edge scientific presentations and comprehensive educational content.



HMP will have one presentation on each of the three novel kinase inhibitors, as follows:




Title:

A Phase Ib study of VEGFR inhibitor fruquintinib in patients with pre-treated advanced colorectal cancer


Abstract:

#3548


Track:

Gastrointestinal (Colorectal) Cancer


Date & Time:

Saturday, 31 May 2014, 8:00 AM







Title:

First-in-human Phase I study of a selective c-Met inhibitor AZD6094 (HMPL-504/volitinib) in patients with advanced solid tumours


Abstract:

#11111


Track:

Tumour Biology


Date & Time:

Saturday, 31 May 2014, 1:15 PM







Title:

First-in-human (FIH) Phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumours


Abstract:

#2615


Track:

Developmental Therapeutics


Date & Time:

Sunday, 1 June 2014, 8:00 AM




Presentations will be made available at http://chi-med.com/eng/irinfo/presentations.htm. Further information about the 2014 ASCO Annual Meeting and the abstracts are available in Notes to Editors and at am.asco.org.



Ends

Register now or login to post to this thread.